Ancora Advisors LLC Buys 225,330 Shares of Augmedix, Inc. (NASDAQ:AUGX)

Ancora Advisors LLC boosted its stake in Augmedix, Inc. (NASDAQ:AUGX) by 102.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 444,660 shares of the company’s stock after acquiring an additional 225,330 shares during the period. Ancora Advisors LLC’s holdings in Augmedix were worth $1,819,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. bought a new stake in Augmedix in the first quarter worth about $56,000. SG Americas Securities LLC bought a new stake in Augmedix in the first quarter worth about $57,000. Norden Group LLC raised its position in shares of Augmedix by 50.2% in the first quarter. Norden Group LLC now owns 19,152 shares of the company’s stock valued at $78,000 after purchasing an additional 6,401 shares during the period. Symmetry Peak Management LLC bought a new stake in shares of Augmedix in the fourth quarter valued at approximately $88,000. Finally, PEAK6 Investments LLC bought a new stake in shares of Augmedix in the first quarter valued at approximately $112,000. Institutional investors own 87.11% of the company’s stock.

Augmedix Stock Performance

Shares of NASDAQ:AUGX opened at $2.27 on Thursday. The company has a 50 day moving average of $1.15 and a 200 day moving average of $2.82. Augmedix, Inc. has a 12 month low of $0.73 and a 12 month high of $6.25. The company has a quick ratio of 2.04, a current ratio of 2.04 and a debt-to-equity ratio of 0.73.

Augmedix (NASDAQ:AUGX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $13.47 million during the quarter, compared to analysts’ expectations of $13.25 million. Augmedix had a negative net margin of 41.95% and a negative return on equity of 178.34%. On average, sell-side analysts expect that Augmedix, Inc. will post -0.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on AUGX. William Blair lowered shares of Augmedix from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Evercore ISI lowered shares of Augmedix from an “outperform” rating to an “inline” rating and lowered their price target for the company from $5.00 to $1.50 in a research report on Tuesday, May 14th. B. Riley lowered shares of Augmedix from a “strong-buy” rating to a “hold” rating and lowered their price target for the company from $3.00 to $2.35 in a research report on Friday, July 19th. Maxim Group lowered shares of Augmedix from a “buy” rating to a “hold” rating and set a $5.00 price target on the stock. in a research report on Tuesday, May 14th. Finally, Lake Street Capital reissued a “hold” rating on shares of Augmedix in a research report on Monday, July 22nd. Four research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.09.

Augmedix Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.